Latest Breaking News On - Paul lyne - Page 1 : vimarsana.com

Merck KGaA and Caris enter oncology partnership worth over $1 4bn

Merck KGaA and Caris enter oncology partnership worth over $1 4bn
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Paul lyneBrian lamonCaris life sciencesMerck kgaMerck kgaaCaris discovery

Merck KGaA signs $1 4B biobuck ADC deal with Caris

Merck KGaA signs $1 4B biobuck ADC deal with Caris
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Sutro biopharmaPaul lyneAbbvie elahereMerck kgaMerck kgaaFlatiron healthTexa caris life sciencesRoche owned flatiron health

Historic District overlay defeated

The Logan Joint Cities/County Planning Commission recently held a hearing to decide if the historic district overlay proposed by the Historic Preservation Board would be recommended as presented, not recommended,

City of russellvilleUnited statesLogan countyHenry parkersPaul lyneDwight cockrillRenee erbCalvin taylorLogan county chamberLogan joint cities county planning commissionRussellville city councilLogan jointCounty planning commissionHistoric preservation boardBlack bottoms districtMichael morrow

Merck KGaA and Mersana partner in potential $830m deal

Merck KGaA and Mersana partner in potential $830m deal
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Paul lyneAnna protopapasMerck kgaMerck kgaaMersana therapeutics

Mersana Therapeutics, Inc : Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates

Collaboration focuses on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana's proprietary immunostimulatory platform Mersana to receive $30 million upfront payment, up to $800

United kingdomImmunosynthen adcsPaul lyneJason fredetteAnna protopapasExchange commissionMerck kgaMerck kgaaMersana therapeutics incHead of research unitResearch unitChief executive officerPrivate securities litigation reform actQuarterly report